Article Text

Download PDFPDF
Meta-variability of advice on drugs in the breastfeeding mother: the example of β-blockers
  1. R Davanzo1,
  2. L Rubert1,
  3. C Oretti1
  1. 1
    Neonatal Intensive Care Unit, Istituto per l’Infanzia IRCCS Burlo Garofolo, Trieste, Italy
  1. Dr R Davanzo, IRCCS Burlo Garofolo, Via dell’Istria 65/1, I-34100 Trieste, Italy; davanzor{at}burlo.trieste.it

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Doctors are often asked to express an opinion on the infant safety profile of a drug taken by the breastfeeding mother. Information available in textbooks or on the internet is not always exhaustive. In fact, scientific evidence on medication safety profile during lactation is often lacking, due to difficulties in study design and, probably, limited interest on this issue by pharmaceutical industry. To avoid any litigation on potential side effects to the nursing infant, pharmaceutical companies generally prefer to warn against the use of any drug. As a consequence, …

View Full Text

Footnotes

  • Competing interests: None.

  • The study was not supported by manufacturers of drugs.